| Pack Size | Qty | Lead Time | Price | Quantity |
Lot Number
CAS #
*This document is like a lab demo—an example Certificate of Analysis (COA) that showcases what a COA looks like but may not match the latest batch in all its glory. Think of it as a chemistry experiment: close, but not quite the final reaction!
Share
Total BLR Stock
:
Bulk Quote| IUPAC name | potassium;bromide |
| canonical smiles | [K+].[Br-] |
| inchi | InChI=1S/BrH.K/h1H;/q;+1/p-1 |
| inchi key | IOLCXVTUBQKXJR-UHFFFAOYSA-M |
| molecular formula | BrK |
| synonyms | |
| Compound Description |
| Molecular Weight: | 119.00 g/mol |
| Hydrogen Bond Donor Count: | 0 |
| Hydrogen Bond Acceptor Count: | 1 |
| Rotatable Bond Count: | 0 |
| Exact Mass: | 117.88204 g/mol |
| Monoisotopic Mass: | 117.88204 g/mol |
| Topological Polar Surface Area: | 0 Ų |
| Heavy Atom Count: | 2 |
| Formal Charge: | 0 |
| Complexity: | 2 |
| Isotope Atom Count: | 0 |
| Defined Atom Stereocenter Count: | 0 |
| Undefined Atom Stereocenter Count: | 0 |
| Defined Bond Stereocenter Count: | 0 |
| Undefined Bond Stereocenter Count: | 0 |
| Covalently-Bonded Unit Count: | 2 |
| Compound Is Canonicalized: | Yes |
| Related Compounds |
| hazard signal | Warning |
| hazard classes and categories | |
| precautionary statement codes | P260, P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 |
| hazard statements | |
| hazards summary | May cause CNS depression in large doses. Findings in poisoning cases after ingestion of 12-50 grams include vomiting, diarrhea, kidney failure, liver injury, and hemolysis. Bromide salts were used in the past as sedatives. Not a skin irritant. Ingestion of large amounts will cause nausea and vomiting. No concern for chronic effects when used in sanitizers for food processing equipment. See Bromine. |
| toxicity summary | IDENTIFICATION AND USE: Potassium bromide is a solid. Potassium bromide may be utilized for the production of photographic-grade silver bromide, in process engraving, and lithography. Other uses for potassium bromide are in clear completion fluids in the petroleum industry, as a pharmaceutical intermediate, and in the manufacture of fibers. It has been used therapeutically in human and veterinary medicine. HUMAN STUDIES: A 3-year-old girl experienced bromoderma tuberosum following potassium bromide treatment for epilepsy. The symptoms disappeared after reduction of the bromide dose. Two iodine-sensitive women in whom potassium bromide solution was used as a radiocontrast agent for retrograde pyelography developed similar clinical conditions culminating in renal failure. Renal failure was due to upper urinary tract obstruction from fibrosis and fat necrosis in each case. Ingestion of potassium bromide at 12-50 g/man caused vomiting, diarrhea, gastritis, anuria, acute nephrosis, uremia, degeneration of neurons and proximal tubules of kidney, fatty degeneration of kidney and liver, edema in brain and kidney, hemolysis, then death 5 days later. ANIMAL STUDIES: Potassium bromide, phenobarbital, or a combination of both is commonly used in the treatment of canine epilepsy. Several cases of clinical pancreatitis have been reported in dogs after treatment with potassium bromide. In a retrospective study, at least 10% of dogs receiving potassium bromide/phenobarbital combination therapy, compared with 0.3% of dogs receiving phenobarbital monotherapy, had probable pancreatitis. Pancreatitis may be a more frequent and more serious adverse effect of potassium bromide/phenobarbital combination therapy than has been reported previously. Bromide toxicosis was diagnosed in an 8-year-old Labrador Retriever that had been treated for epilepsy with potassium bromide, at a dosage of 29 mg/kg of body weight/d. Clinical signs included hind limb weakness, ataxia, and disorientation. Renal insufficiency, diagnosed by determination of endogenous creatinine clearance, was believed to be responsible for the development of bromide toxicosis in this dog. Two cases of panniculitis associated with administration of potassium bromide in dogs are reported. Both dogs were treated with potassium bromide for idiopathic epilepsy for over 1 year. Dose increases in both cases were associated with panniculitis, characterized by painful subcutaneous nodules in a generalized distribution over the trunk. Nodule eruption waxed and waned in one dog and was persistent in the other. In both cases, panniculitis was accompanied by lethargy and pyrexia. ECOTOXICITY STUDIES: The effects of potassium bromide on the aquatic organisms were far smaller than those of potassium bromate and sodium bromate. |
| symptoms |
